Testosterone Therapy Heart Attacks
Low testosterone, or “Low T”, is a medical condition that may affect men’s sex drive, mood, energy levels, muscle mass, and bone strength. A variety of methods to increase testosterone levels are marketed to men in the form of Androgel®, Axiron®, patches, injections, gels, and pills. But testosterone therapy has been linked to an increased risk of heart attack and other severe health problems in some male patients.
If you or someone you love suffered a heart attack, pulmonary embolism, or stroke or developed deep vein thrombosis after using a testosterone therapy product, Ferrer, Poirot & Wansbrough can help. Our drug injury lawyers fight for victims like you who are injured and suffering. Contact us today—just dial (800) 210-8503 or fill out a free initial consultation form.
Studies on Testosterone Treatment and Heart Risk
A recent study concluded that men under age 65 with a history of heart disease were twice as likely to have heart attacks using testosterone treatments than after using erectile dysfunction drugs—which are also marketed as methods to increase male sexual performance.
The study also revealed that the risk of heart attacks doubled during the first three months of beginning testosterone replacement therapy in men under age 65 who have a history of heart disease. The risk of heart attack also doubles in all men over age 65—regardless of their heart health history.
Low T Treatment Linked to Heart Attack, Stroke, and Death
The U.S. Food and Drug Administration (FDA) is investigating the link between testosterone treatments and cardiovascular problems.
In addition to heart attacks, men who use AndroGel and other testosterone products may face an increased risk of:
- Deep vein thrombosis (DVT),
- Pulmonary embolism,
- and even death.
Testosterone Treatment FAQ
Our drug injury lawyers are here to answer your questions about Low T treatment. Some of the questions we often hear from our clients include:
Has the U.S. Food and Drug Administration (FDA) issued any warnings about testosterone treatment drugs?
The FDA released a safety communication announcing an investigation into the risk of stroke, heart attack, and death in men taking FDA-approved testosterone therapies. In addition, FDA officials cautioned doctors to weigh the potential risks and benefits of testosterone treatments before prescribing drugs to treat Low T.
Does testosterone therapy cause heart disease or heart attacks?
Recent studies have shown an increased risk of cardiovascular issues—including heart attack, stroke, and death—in men who take FDA-approved testosterone therapies. In a study published in January 2014, the risk of heart attack doubled during the first three months of testosterone therapy for men under age 65 who had a history of heart disease. The risk also doubled for male patients over age 65—regardless of their heart health history.
Want to learn more? Click here to find answers to other frequently asked questions about testosterone therapy dangers.
Testosterone Therapy Lawsuits
Men who have suffered cardiovascular problems caused by Low T treatments may be able to file lawsuits seeking compensation for their pain and suffering, medical bills, and lost wages. At Ferrer, Poirot & Wansbrough, we have more than 30 years of experience helping drug injury victims, and we can help protect your legal rights to compensation.
Our law firm forces corporations to take responsibility for their negligence when they put profits over safety. And you won’t pay out of pocket costs unless we get money for you. So don’t wait—contact our legal staff today. We’re available to take your call 24 hours a day, seven days a week.
AndroGel® is a registered trademark of Unimed Pharmaceuticals, LLC, and is used here only to identify the product in question. Axiron® is a registered trademark of Lilly USA, LLC, and is used here only to identify the product in question.
This law firm is not affiliated with, sponsored by, or associated with Lilly USA, LLC, Forbes.com LLC, Unimed Pharmaceuticals, LLC, or the U.S. Food and Drug Administration.